PellePharm

aka PellePharm, Inc.

PellePharm is a Californian company, an affiliate of BridgeBio, that reformulated the Hedgehog inhibitor patidegib as a skin gel to prevent basal cell carcinomas in people with Gorlin syndrome.

PellePharm develops patidegib topical gel (formerly saridegib, IPI-926), a Hedgehog pathway inhibitor applied to the skin to block the Smoothened receptor in basal cell carcinomas without the taste loss, hair loss and muscle cramps of oral Hedgehog inhibitors. The drug is aimed at Gorlin syndrome (basal cell nevus syndrome), where patients develop many tumours over a lifetime, and at high-frequency sporadic basal cell carcinoma. A phase 3 trial in Gorlin syndrome completed enrolment in 2020 but did not meet its primary endpoint.

Headquarters

Menlo Park, California, US

Scorecard

All companies

#410of 1181 companies, score 7

phase 3 +3
targets +2
modalities +2

0 approved, 1 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.

Type

biotech

Products

1top

Phase 3Topical hedgehog pathway (SMO) inhibitor gel

Patidegib

Patidegib is a hedgehog-pathway blocker made into a skin gel. It is being tested in people with Gorlin syndrome, who grow dozens of basal cell carcinomas, to prevent new tumours without the hair loss, muscle cramps and taste loss that the oral drugs cause.

Connected